Z-Tech, an ICF International Company at US FDA's National Center for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, USA.
Expert Rev Mol Diagn. 2011 Apr;11(3):333-43. doi: 10.1586/erm.11.3.
DNA sequencing is a powerful approach for decoding a number of human diseases, including cancers. The advent of next-generation sequencing (NGS) technologies has reduced sequencing cost by orders of magnitude and significantly increased the throughput, making whole-genome sequencing a possible way for obtaining global genomic information about patients on whom clinical actions may be taken. However, the benefits offered by NGS technologies come with a number of challenges that must be adequately addressed before they can be transformed from research tools to routine clinical practices. This article provides an overview of four commonly used NGS technologies from Roche Applied Science//454 Life Sciences, Illumina, Life Technologies and Helicos Biosciences. The challenges in the analysis of NGS data and their potential applications in clinical diagnosis are also discussed.
DNA 测序是解码许多人类疾病(包括癌症)的有力方法。下一代测序(NGS)技术的出现将测序成本降低了几个数量级,并显著提高了通量,使得全基因组测序成为获得可能对接受临床治疗的患者进行全球基因组信息的一种方法。然而,NGS 技术带来的好处也带来了许多挑战,在这些技术从研究工具转化为常规临床实践之前,必须充分解决这些挑战。本文概述了罗氏应用科学//454 生命科学、Illumina、生命技术和 Helicos 生物技术公司的四种常用 NGS 技术。还讨论了 NGS 数据分析中的挑战及其在临床诊断中的潜在应用。